Millennium Velcade Has 50%-60% Of Third-Line Multiple Myeloma Market
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Millennium’s Velcade captured 50% to 60% of the third-line multiple myeloma market in the second quarter, the firm reported July 22.